Seminari de Recerca "miR-424/503 modulates Wnt/β-catenin signaling in the mammary epithelium by targeting LRP6"

 Seminaris
  1. Vall d'Hebron Institut de Recerca - VHIR (Edifici Collserola) - Edifici Collserola — Ver en el mapa
05/10/2022
05/10/2022 -- De 12:00h a 13:00h
Organize :
Recerca Vall d'Hebron
Modality: Presencial
Compártelo:
Seminari de Recerca "miR-424/503 modulates Wnt/β-catenin signaling in the mammary epithelium by targeting LRP6"

Dr. Ruth Rodríguez Barrueco, Principal Investigator, Molecular Oncology Center, Oncologic Research Institute - Bellvitge Biomedical Research Institute-IDIBELL

Breast cancer is the most frequently diagnosed tumor among women, and the leading cause of female cancer death. Mammographic screening coupled with improved treatments have led to a striking increase of survival in both early and advanced settings. However, most patients presenting advanced disease will eventually progress, with more than 90% of the patients dying from metastatic breast cancer. Tumor progression and metastatic spread require high cell plasticity to quickly adapt to new scenarios and escape the immune system. Cellular metabolism largely influences the promotion and maintenance of stemness in breast cancer. The specific events, and the mechanisms by which they are controlled, require further exploration.
Previous work of our laboratory demonstrated that decreased levels of the cluster of miRNAs 424(322)/503 induce stem characteristics to normal mammary cells. Accordingly, we have recently reported that the miR-424(322)/302 cluster is a novel modulator of canonical Wnt signaling in the mammary epithelium that exerts its function by decreasing the expression of the LRP6 co-receptor. Moreover, the cluster is required for Wnt-mediated MaSC expansion induced by the ovarian cycles. 
In the context of breast cancer, the suppression of the expression of these two miRNAs in a murine model promotes hyperplasia in the mammary glands and multifocal thickening of the TDLUs (Terminal Ductal Lobular Units). We have also described that the cluster of mi-R-424(322)/503 is deleted in a group of aggressive breast tumors and reported that miR-424(322)/503 knockout mice develop mammary tumors over time which are promoted by pregnancy. These are undifferentiated tumors that resist to chemotherapeutic agents thanks to the increased expression of their target genes BCL-2 and IGF1R. We have also associated the loss of expression of miR-424(322)/503 to the acquisition of plasticity necessary to switch amongst stages and to the rewiring of major energy-producing pathways. Mechanistically, miR-424(322)/503 regulates pluripotency and metabolism via direct targeting of zinc finger protein 217 (ZNF217). Repression of this transcription factor was sufficient to reverse the stem-like and metabolic phenotypes revealing a new role of ZNF217 in mammary epithelial cells and opening the avenue to new targeted therapies for aggressive breast tumors. 

Host: Dr. Miquel Segura, Senior researcher Childhood Cancer and Blood Disorders (VHIR)

Actividades relacionadas

Introducción a la hidrocefalia y alteraciones de la dinámica de LCR

02/09/2024 - 09:00
Más información

XIX Curso teórico-práctico de Ecocardiografía básica y avanzada en medicina de urgencias, intensiva y anestesia

16/09/2024 - 09:00
Cardiología, Medicina Intensiva, Anestesia y Reanimación, Neurología
Más información

Fundamentos fisiopatológicos de la hipoxia tisular y monitorización del aporte cerebral de oxígeno

30/09/2024 - 09:00
Facultativos especialistas, residentes y personal de enfermería interesados ​​en el manejo del paciente neurocrítico
Más información

II Curso CARE ME

03/10/2024 - 08:45
Cardiología y Nefrología
Más información

Subscríbete a nuestros boletines y forma parte de la vida del Campus

Selecciona el boletín que quieres recibir:

La aceptación de estas condiciones, supone que da el consentimiento al tratamiento de sus datos personales para la prestación de los servicios que solicita a través de este portal y, si procede, para hacer las gestiones necesarias con las administraciones o entidades públicas que intervengan en la tramitación, y su posterior incorporación en el mencionado fichero automatizado. Podéis ejercitar los derechos de acceso, rectificación, cancelación y oposición dirigiéndoos por escrito a web@vallhebron.cat, indicando claramente al asunto "Ejercicio de derecho LOPD".
Responsable: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Finalidad: Gestionar el contacto del usuario.
Legitimación: Aceptación expresa de la política de privacidad.
Derechos: Acceso, rectificación, supresión y portabilidad de los datos, limitación y oposición a su tratamiento.
Procedencia: El propio interesado.